The relationship between non-alcoholic fatty liver disease and breast cancer: a retrospective case-control study

Year 2022, Volume: 5 Issue: 1, 109 - 113, 17.01.2022

Sevde Nur Fırat , Abdullah Durhan , Serap Erel , Cavit Çulha

https://doi.org/10.32322/jhsm.993960

Abstract

Aim: Breast cancer is the most common cancer among women and is one of the main causes of death in women. It is known that some metabolic components that are risk factors for non-alcoholic fatty liver disease are also risk factors for breast cancer. The aim of this retrospective cohort study was to show the prevalence of non-alcoholic fatty liver disease breast cancer patients and the effect of non-alcoholic fatty liver disease on breast cancer development through comparisons with a control group with normal mammography.
Material and Method: The study included 108 patients who were operated on for breast cancer in the general surgery clinic of our hospital between January 2015 and December 2018 and who underwent abdominal ultrasound for breast cancer staging. A control group was formed of 102 women with benign breast lesions on routine mammography and who underwent abdominal ultrasound within 6 months before mammography. The prevalence of diabetes, hypertension and hyperlipidemia and body mass indexes were similar in both groups.
Results: In the evaluation of all the study participants, an association was found between non-alcoholic fatty liver disease and breast cancer. In the obese and non-obese subgroups, non-alcoholic fatty liver disease was significantly associated with breast cancer in the non-obese subgroup. [OR 2.67%, 95% confidence interval [95% CI) 1.1-6.0, p=0.020].
Conclusion: Non-alcoholic fatty liver disease was seen to be significantly associated with breast cancer regardless of known risk factors. This relationship there was in non-obese women with NAFLD, but not in the obese group.

Keywords

Breast cancer, nonalcholic fatty liver disease, non-obese women

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: 359-86.
• Suh JS, Yoo KY, Kwon OJ, et al. Menstrual and reproductive factors related to the risk of breast cancer in Korea. Ovarian hormone effect on breast cancer. J Korean Med Sci 1996; 11: 501-8.
• Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Annals of Internal Medicine 2012; 156: 635-48.
• Bhandari R, Kelley GA, Hartley TA, Rockett IR. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int J Breast Cancer 2014; 2014: 189384.
• Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut 2011; 60: 745-6.
• Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ (Clinical research ed) 2015; 350: g7607.
• Nseir W, Abu-Rahmeh Z, Tsipis A, Mograbi J, Mahamid M. Relationship between non-alcoholic fatty liver disease and breast cancer. The Israel Medical Association J: IMAJ 2017; 19: 242-5.
• Kwak MS, Yim JY, Yi A, et al. Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. Dig Liver Dis 2019; 51: 1030-5.
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama 2015; 313: 2263-73.
• D’Orsi CJ SE, Mendelson EB, Morris EA, et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA, American College of Radiology; 2013.
• Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. Jama 2001; 285: 769-76.
• Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. Jama 1998; 279: 535-40.
• Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22: 2687-92.
• Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49: 89-96.
• Cave M, Deaciuc I, Mendez C, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007; 18: 184-95.
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014; 20: 6212-22.
• Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-63.
• Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci 2016; 17: 717.
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62: 47-64.
• Lee YS, Lee HS, Chang SW, et al. Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. Medicine 2019; 98: e17277.
• Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-85.
• Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7392-402.
• Pinto HC, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis--report of three cases. J Hepatol 1995; 23: 95-7.
• Yang YJ, Kim KM, An JH, et al. Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. Breast 2016; 28: 67-72.